• Ave. 31 No. 15802 between 158 y 190, Cubanacán, Playa, Havana. C.P. 11600, P.O. Box 6162
  • webmaster@cigb.edu.cu
  • (53) 7-2504101; (53) 7-2716022
B-8
previous arrow
next arrow

Message from the Director General

“We have been able to motivate young people to become what we have become. We had the opportunity to work with a very committed generation, and we have a duty to follow that example.”

Our studies focus on

Research areas

that generate a positive impact on human, animal and plant health, as well as industrial productions, in harmony with the environment, to contribute to the socioeconomic development of Cuba

Our directives

Abdala

First vaccine against COVID-19 in Latin America.

Results

Phase III clinical study of Abdala

Efficacy against symptomatic disease
92.28%
Efficacy in preventing severe systemic disease and death of vaccinated people
100%
Effectiveness in critically ill patients
90%
Upcoming events

Where you can know our results

We work for one health

We offer + 25 products

Our products are preventive, therapeutic or diagnostic. We design products first and only of its kind for diseases that have no other effective therapeutic solutions.

What do we work on?

Main processes